MIRUM PHARMACEUTICALS INC

MIRM is the stock ticker for Mirum Pharmaceuticals, Inc., a biopharmaceutical company traded on the Nasdaq Global Select Market. The stock represents ownership in a clinical-stage and commercial-stage company focused on developing and commercializing therapies for rare liver diseases and other underserved conditions. Investors track MIRM as a way to participate in the growth potential of a specialty pharmaceutical business.

Recent performance for MIRM depends on the latest trading session and market conditions. You can find the most up-to-date recent performance data on the MIRM stock detail page, including daily price changes, percentage moves, and short-term trends. That information reflects the latest available trading activity rather than any historical figures that may no longer be current.

Evaluating MIRM's valuation typically involves looking at metrics such as price-to-sales, price-to-book, and enterprise value relative to revenue, since the company may have limited or no earnings. Analysts also consider pipeline potential, commercial product sales, and cash position. Because MIRM operates in the biopharmaceutical sector, traditional P/E ratios may be less meaningful. Refer to the latest valuation data on the MIRM stock page for current figures.

MIRM's trading activity varies based on market interest, news, and overall liquidity. It is listed on the Nasdaq Global Select Market, which generally supports active trading, but daily volume can fluctuate. To check how actively MIRM is trading, review the current volume and average volume figures shown on the MIRM stock detail page.

Important metrics for MIRM include revenue growth, product sales, gross margin, operating expenses, net loss or income, cash and cash equivalents, and research and development spending. Because MIRM is a biopharmaceutical company, pipeline progress and commercial launch metrics also matter. These figures help investors assess financial health and the path toward profitability. Current data is available on the MIRM stock page.

Key risks for MIRM include clinical trial failures, regulatory setbacks, competition from other therapies, reliance on key products or pipeline candidates, and the need for additional capital. As a biopharmaceutical company, MIRM also faces risks related to drug pricing, reimbursement, and intellectual property protection. Market volatility and broader economic conditions can further affect the stock.